The global neurological disorders drugs market is anticipated to grow at a CAGR of 6.4% during the forecast period (2022-2028). The rising prevalence of neurological disorders has been witnessed over the years. Finding drugs for the central nervous system is a very challenging and complex task due to the involvement of the blood-brain barrier, P-glycoprotein, and the drug's high attrition rates. The availability of big data present in online databases and resources has enabled the emergence of artificial intelligence techniques including machine learning to analyze, process the data, and predict unknown data with high efficiency. To combat this trend, many researchers are turning to artificial intelligence (AI), which has proved useful for identifying complex disorders and aiding in optimized interventions. AI technology predicts cognitive impairment and anticipates how severely motor skills might decline over time thereby supporting accelerating patient diagnoses and improving prognoses for neurodegenerative diseases.
Browse the full report description of “Neurological Disorders Drugs Market Size, Share & Trends Analysis Report, By Indication (Epilepsy, Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/neurological-disorder-drugs-market-size
The primary concern associated with drug design and development is time consumption and manufacturing cost. Further, inefficiency, inaccurate target delivery, and inappropriate dosage are other hurdles that inhibit the process of drug delivery and development. With advancements in technology, computer-aided drug design integrating artificial intelligence algorithms is being used to eliminate the challenges and hurdles of traditional drug design and development. Also, the new deep learning architectures proposed in many recent works have given a better understanding of how artificial intelligence can tackle big complex problems that arose due to central nervous system disorders. For instance, in July 2022, Insilico Medicine, in collaboration with Answer ALS—a global research project working to assemble a massive repository of patient and sample data, has claimed to identify untapped genomic targets using its artificial intelligence programs that could provide avenues to new treatments for amyotrophic lateral sclerosis and potentially rescue patients from the neurodegenerative effects of the disease better known as ALS.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Indication
o By Distribution Channel
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- AstraZeneca plc, AbbVie Inc., GlaxoSmithKline plc, Novartis International AG, and Pfizer Inc.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Neurological Disorders Drugs Market Report by Segment
By Indication
By Distribution Channel
Global Neurological Disorders Drugs Market Report by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/neurological-disorder-drugs-market-size